RxDoctor Payments Data

Mario Profet, MD

General Practice · Tampa, FLNPI 1487795092

Payments from drug & device makers

$3,063in general payments, 2019–2025

Across 108 payments — averaging $28.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$885
  • Johnson & Johnson$703
  • Amarin Pharma, Inc.$402
  • Novartis$203
  • Amgen$185
  • Sanofi-aventis U.S. LLC$128
  • plus $558 from 9 others

What the payments were for

  • Food & beverage$3,052100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,063 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$4,230
Medicare patients
14
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide65$84,532
FarxigaDapagliflozin Propanediol68$70,003
JardianceEmpagliflozin52$68,053
EliquisApixaban41$41,946
OzempicSemaglutide22$30,799
JanuviaSitagliptin Phosphate27$26,896
EntrestoSacubitril/Valsartan19$21,889
VascepaIcosapent Ethyl20$21,865
XareltoRivaroxaban13$15,844
SymbicortBudesonide/Formoterol Fumarate31$10,902
BrilintaTicagrelor15$10,198
Lantus SolostarInsulin Glargine,hum.Rec.Anlog72$8,941
TradjentaLinagliptin13$6,539
Fluticasone-SalmeterolFluticasone Propion/Salmeterol42$6,153
Breo ElliptaFluticasone/Vilanterol11$5,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort, Brilinta$885$91,104114 claims
Lilly USA, LLCTrulicity$99$84,53265 claims
Boehringer IngelheimJardiance, Tradjenta$54$74,59265 claims
PfizerEliquis$30$41,94641 claims
Novo NordiskOzempic$116$30,79922 claims
NovartisEntresto$203$21,88919 claims
Johnson & JohnsonXarelto$703$15,84413 claims
GSKBreo Ellipta$62$5,11011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,901 general practice providers in Florida.

Other general practice in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →